Category:

Menasha has created a solution to educate pharmacists about front-of-store items that can not only provide better care for patients with chronic conditions and improve adherence, but also encourage basket-building among patients…Menasha’s Paul Murphy, senior director of retail sales and new business development,…bridge the merchandising strategy gap between pharmacists and front-of-store, which can help improve care. (video)

There’s little chance US companies will consider Iran as a venue for pharmaceutical contract manufacturing, even in the current era of limited détente…second-biggest economy in the Middle East and has a large pharmaceutical sector…nuclear agreement…even if passed by Congress, doesn’t include any commitment to remove sanctions that may restrict direct manufacturing activities..

study of venom in medicine has traditionally been confined to understanding its effect as a toxin..But scientists are becoming increasingly interested in studying venom systems...to discover ingredients to make new drugs… a new technique for "milking" the Australian box jellyfish of its deadly venom,...method that he and his colleagues have developed is practical and highly efficient, and it promises to remove a major bottleneck in the field of jellyfish venom research.

Wal-Mart's second quarter earnings release this week highlighted one of the many effects of more people gaining health insurance under the Affordable Care Act: its pharmacies are no longer as profitable… is seeing lower reimbursement rates from drug insurance plans and a decline in high-margin cash transactions… one of the dirty secrets of the pharmacy industry that uninsured people frequently pay more for drugs than those with insurance…

Huntington Memorial Hospital..it had alerted health authorities about a potential link between patients who have a pseudomonas bacteria and the Olympus Corp. duodenoscopes used to treat them… Federal regulators have attributed this to a design flaw that makes the tip of these instruments hard to clean even when following the manufacturers' guidelines.

Concerns over the state of China's economy have hit world stock markets this week, yet one group of Western companies could benefit from regulatory developments…a decision…to speed up the review process for some of their products is being seen…offering a potential boost,… China's Food & Drug Administration said… the country aimed to "set up a more scientific and efficient system to ensure the safety and quality of medicines…appraisal and approval process of innovative drugs will be accelerated..

Valeant Pharmaceuticals International Inc. is nearing a deal to pay $1 billion for the closely held company (Sprout Pharmaceuticals Inc) that just won approval to sell the first drug that aims to boost a woman’s libido,..Valeant would pay all cash, one $500 million installment upfront and one next year,..Valeant would also take on all of Sprout’s 25 employees, including its leadership team, as they complete preparations to begin sales of the drug in October,…

Lundbeck has initiated a rejig of its pipeline, taking an ax to undisclosed early-stage assets in order to funnel cash into.. its most promising candidates…schizophrenia drug Lu AF35700 is among the beneficiaries… many of the drugs that are available..predominantly driving effects through D2 (receptor).. 35700..has a strong binding affinity to the D1 receptor… hopes to differentiate its pipeline candidate… through its side effect profile, giving patients who are resistant to D2-targeted drugs a treatment option that doesn't cause weight gain and metabolic disturbances.

Picking apart biopharma’s protracted boom,…the vibe that getting drugs approved is simply much easier than it once was…. FDA has been green-lighting new drugs at an escalating rate for the past few years… some think the agency can go farther… 21st Century Cures Act,..contains a bevy of provisions designed to bring medicines to the market more quickly…The bill has faced staunch criticism from public health officials and media outlets, cautioning that there can be too much of a good thing, and improperly evaluated drugs can be just as dangerous to patients as no treatments at all.

Companies vie for enrollees amid questions that trials will siphon participants away from each other…After years of effort, scientists and families of young patients with the genetic condition Niemann-Pick Type C are in a position to which any rare-disease community aspires: the prospect of not one, not two, but three companies launching clinical trials to develop therapies…the flurry of commercial interest has sparked an urgent debate. Can the community support more than one trial at the same time?